liquid biopsy

First-void urine has emerged as a promising sample type for cancer diagnostic test development.

Using a library preparation kit optimized for cell free DNA (cfDNA) provides high quality data for early cancer detection.

Profiling genetic variants and DNA methylation changes in cell free DNA could transform the detection of cancers including hepatocellular carcinoma.

A multiomic sequencing approach helps scientists capture more biomarker information through liquid biopsy.

Liquid biopsies: A new era in blood-based cancer detection methods

After controlling for high levels of bacterial contamination in their lab and reagents, researchers detect microbial genetic material in plasma samples from healthy people and cancer patients.

In the largest effort to date to standardize performance metrics of the cancer diagnostic across products, researchers say the products can likely detect advanced tumors reliably, but early-stage malignancies would remain a challenge.

The liquid biopsy, which detects cell-free tumor DNA, spotted undiagnosed cancers in some women, but had a greater number of false positives and false negatives.

Machine-learning algorithms tuned to detecting cancer DNA in the blood could pave the way for personalized cancer care.

The test can pick up several types of cancer, including pancreatic and ovarian, years before symptoms appear.

The new diagnostic works by identifying cancer-associated proteins and DNA in patient blood.

The genomics pioneer shares the sessions she most looks forward to at this year’s American Association for Cancer Research annual meeting.